Stany Zjednoczone - angielski - NLM (National Library of Medicine)

professional disposables international, inc. - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - benzalkonium chloride 0.13 ml in 1 ml - antiseptic handwash

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

proandre, sl - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - benzalkonium chloride 0.1 mg in 1 ml - active ingredient purpose benzalkonium chloride 0.1%....................antibacterial uses * helps to eliminate bacteria on hands. avoid contact with broken skin * wash for 15-20 seconds * rinse and dry hands thoroughly. * children under 6 years of age should be supervised by an adult when using this product * helps to eliminate bacteria on hands. avoid contact with broken skin * irritation and redness develops.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

target corporation - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y), lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - benzalkonium chloride .192 g in 147.8 ml - purpose benzalkonium cl 0.13% w/w ........ first aid antiseptic lidocaine hcl 2.5% w/w................pain relieving spray uses   •first aid to help bacterial contamination or skin infectionand for temporary relief of of pain and itching associated with minor  •cuts  •scrapes  •burns  •sunburn  •skin irritations

Australia - angielski - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - budesonide, quantity: 2 mg - foam - excipient ingredients: propylene glycol; purified water; emulsifying wax; cetyl alcohol; citric acid monohydrate; disodium edetate; butane; isobutane; propane; steareth-10 - budenofalk foam is indicated in the treatment of active rectal and rectosigmoid disease in ulcerative colitis.

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - benzalkonium cl(250g/l) - quaternary ammonium

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

alk-abello a s - ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3) - ambrosia artemisiifolia pollen 12 [amb'a'1'u] - ragwitek® is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific ige antibodies for short ragweed pollen. ragwitek is approved for use in persons 5 through 65 years of age. ragwitek is not indicated for the immediate relief of allergic symptoms. ragwitek is contraindicated in patients with: - severe, unstable or uncontrolled asthma - a history of any severe systemic allergic reaction - a history of any severe local reaction after taking any sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product [see description ( 11 )]. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarr

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

alk-abello a s - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg) - phleum pratense pollen 2800 [bau] -       grastek®  is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro  testing for pollen-specific ige antibodies for timothy grass or cross-reactive grass pollens. grastek is approved for use in persons 5 through 65 years of age.       grastek is not indicated for the immediate relief of allergic symptoms.       grastek is contraindicated in patients with: - severe, unstable or uncontrolled asthma  - a history of any severe systemic allergic reaction - a history of any severe local reaction after taking any sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients [gelatin, mannitol and sodium hydroxide] contained in this product [ s ee description ( 11 )].       risk summary       all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated b

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

alk-abello a s - dermatophagoides pteronyssinus (unii: 57l1z5378k) (dermatophagoides pteronyssinus - unii:57l1z5378k), dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q) - dermatophagoides pteronyssinus 6 [arb'u] - odactra™ is an allergen extract indicated as immunotherapy for the treatment of house dust mite (hdm)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for ige antibodies to dermatophagoides   farinae or dermatophagoides   pteronyssinus house dust mites, or by positive skin testing to licensed house dust mite allergen extracts. odactra is approved for use in persons 12 through 65 years of age.  odactra is not indicated for the immediate relief of allergic symptoms. odactra is contraindicated in patients with: - severe, unstable or uncontrolled asthma - a history of any severe systemic allergic reaction - a history of any severe local reaction after taking any sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients contained in this product [see description ( 11 )] risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on odactra administered to pregnant women are insufficient to inform associated risks in pregnancy. in an embryo/fetal developmental toxicity study performed in mice, administration of odactra during gestation did not reveal adverse developmental outcomes in fetuses (see 8.1 data ). data animal data in a developmental toxicity study, the effect of odactra on embryo/fetal development was evaluated in mice. animals were administered odactra subcutaneously daily from day 6 to day 17 of the gestation period at doses up to 5 times the human sublingual dose. there were no odactra-related post-implantation losses, fetal malformations or variations. risk summary it is not known whether odactra is excreted in human milk. data are not available to assess the effects of odactra on the breastfed child or on milk production and excretion in the nursing woman. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for odactra and any potential adverse effects on the breastfed child from odactra or from the underlying maternal condition. the safety and effectiveness of odactra have been established in adolescents 12 through 17 years of age. the safety and effectiveness have not been established in persons below 12 years of age. safety and effectiveness have not been established in persons older than 65 years of age.

Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

natural wellness industries sdn. bhd. (milik penuh nutrivention sdn. bhd) - benzalkonium chloride; cetrimide -

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - benzalkonium chloride; triclosan; light liquid paraffin - bath additive - 52.5/6/2 percent weight/weight - quaternary ammonium compounds; benzalkonium